Core Viewpoint - Runmed-B (02297) experienced a significant intraday increase of 32.43%, reaching a price of 0.49 HKD per share with a trading volume of 18.92 million HKD [1]. Group 1: Company Overview - Runmed Medical Co., Ltd. aims to become a global leader in vascular interventional surgical robots, with key products including the caFFR system, caIMR system, and FlashBot vascular interventional surgical robot [1]. - The company has established a global network for research and development, production, sales, and service, collaborating with top medical centers and implementing a strict quality inspection system [1]. - Runmed has successfully obtained certification for its medical device quality management system [1]. Group 2: Financial Performance - As of the 2024 annual report, Runmed-B reported total operating revenue of 39.824 million HKD and a net profit of -113 million HKD [2].
润迈德-B(02297)上涨32.43%，报0.49元/股